Summary:
In this podcast from the 2023 DPHARM meeting, senior industry leaders discussed the pandemic's impact on the abrupt transition to DCTs, and where that leaves us in the current day when it comes to determining the value proposition of patient-enabled tech. They focused on the operating models required for patient-enabled trial technologies, the realities that can propel or stifle innovation, AI's potential for streamline clinical operations, and more.
For more information about DPHARM, visit DPHARMconference.com.
Moderators
Lynn D Kramer, MD, FAAN
Chief Clinical Officer ADBH and Corporate Officer
Eisai Co., Ltd.
Speakers
Andy Lee
SVP, Head of Global Clinical Trial Operations
Merck & Co., Inc.
Kenneth Getz, MBA
Executive Director and Professor
Tufts Center for the Study of Drug Development
Bari Kowal
SVP and Head, Development Operations, Portfolio Management and Biostatistics Data Management
Regeneron
Janice Chang
CEO
TransCelerate BioPharma Inc
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.